Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 50Triple Negative Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 11Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Ovarian Neoplasms 7Melanoma 6Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Urinary Bladder Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Carcinoma, Merkel Cell 3Urogenital Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2HER2-positive Breast Cancer 2Esophageal Neoplasms 2Vulvar Neoplasms 1Urologic Neoplasms 1

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2Fulvestrant 2tucatinib 1palbociclib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Drug Therapy 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × atezolizumab × Breast × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡